Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>

Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2022-06-22 Sale | 2022-06-24 7:51 pm | Athira Pharma Inc. | ATHA | Litton Mark James Chief Executive Officer | 7,960 | $2.69 | $21,412 | 148,244 (Indirect Direct) | View |
2018-06-01 Sale | 2018-06-05 5:40 pm | ALDER BIOPHARMACEUTICALS INC | ALDR | Litton Mark James Chief Business Officer | 22,727 | $17.84 | $405,412 | 180,189 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2023-01-27 Option Award | 2023-01-31 7:33 pm | N/A 2033-01-26 | Athira Pharma Inc. | ATHA | Litton Mark James Chief Executive Officer | 425,000 | $0 | 573,906 (Direct) | View |
2023-01-27 Option Award | 2023-01-31 7:33 pm | N/A N/A | Athira Pharma Inc. | ATHA | Litton Mark James Chief Executive Officer | 662 | $2.74 | 573,906 (Direct) | View |
2022-06-22 Option Award | 2022-06-24 7:51 pm | N/A N/A | Athira Pharma Inc. | ATHA | Litton Mark James Chief Executive Officer | 757 | $7.06 | 148,244 (Direct) | View |
2022-06-22 Option Award | 2022-06-24 7:51 pm | N/A N/A | Athira Pharma Inc. | ATHA | Litton Mark James Chief Executive Officer | 20,000 | $0 | 148,244 (Direct) | View |
2022-01-27 Option Award | 2022-01-31 5:06 pm | N/A 2032-01-26 | Athira Pharma Inc. | ATHA | Litton Mark James Chief Executive Officer | 400,000 | $0 | 535,447 (Direct) | View |
2022-01-27 Option Award | 2022-01-31 5:06 pm | N/A N/A | Athira Pharma Inc. | ATHA | Litton Mark James Chief Executive Officer | 885 | $12.51 | 535,447 (Direct) | View |
2021-08-17 Exercise | 2021-08-19 5:05 pm | N/A 2029-08-14 | Athira Pharma Inc. | ATHA | Litton Mark James Chief Operating Officer | 50,440 | $0 | 235,442 (Direct) | View |
2021-08-17 Exercise | 2021-08-19 5:05 pm | N/A N/A | Athira Pharma Inc. | ATHA | Litton Mark James Chief Operating Officer | 50,440 | $1.35 | 235,442 (Direct) | View |
2021-08-17 Option Award | 2021-08-19 5:05 pm | N/A N/A | Athira Pharma Inc. | ATHA | Litton Mark James Chief Operating Officer | 867 | $14.45 | 235,442 (Direct) | View |
2021-02-18 Option Award | 2021-02-22 5:36 pm | N/A 2031-02-17 | Athira Pharma Inc. | ATHA | Litton Mark James Chief Operating Officer | 85,000 | $0 | 85,000 (Direct) | View |
2020-09-22 Conversion | 2020-09-22 5:15 pm | N/A N/A | Athira Pharma Inc. | ATHA | Litton Mark James Chief Operating Officer | 32,815 | $0 | 70,129 (Direct) | View |
2020-09-17 Ownership | 2020-09-17 8:32 pm | N/A N/A | Athira Pharma Inc. | ATHA | Litton Mark James Chief Operating Officer | 0 | $0 | 281,232 (Direct) | View |
2019-02-06 Option Award | 2019-02-08 4:30 pm | N/A 2028-08-05 | ALPINE IMMUNE SCIENCES Inc | ALPN | Litton Mark James See Remarks | 100,000 | $0 | 100,000 (Direct) | View |
2018-08-06 Option Award | 2018-08-08 6:34 pm | N/A 2028-08-05 | ALPINE IMMUNE SCIENCES Inc | ALPN | Litton Mark James See Remarks | 150,000 | $0 | 150,000 (Direct) | View |
2018-06-01 Exercise | 2018-06-05 5:40 pm | N/A 2019-04-20 | ALDER BIOPHARMACEUTICALS INC | ALDR | Litton Mark James Chief Business Officer | 22,727 | $0 | 180,189 (Direct) | View |
2018-06-01 Exercise | 2018-06-05 5:40 pm | N/A N/A | ALDER BIOPHARMACEUTICALS INC | ALDR | Litton Mark James Chief Business Officer | 22,727 | $0.99 | 180,189 (Direct) | View |
2018-02-16 Option Award | 2018-02-21 5:31 pm | N/A 2028-02-15 | ALDER BIOPHARMACEUTICALS INC | ALDR | Litton Mark James Chief Business Officer | 75,000 | $0 | 75,000 (Direct) | View |